

ENROLLEE INFORMATION

## **NYRx the Medicaid Pharmacy Program**

## PDE-5 Inhibitors for Pulmonary Arterial Hypertension (PAH) **Prior Authorization Worksheet**

Fax Number: 1-800-268-2990

Processing may be delayed if information submitted is illegible or incomplete. If your fax includes the standardized fax form, only the Enrollee Name, Date of Birth, Medicaid ID, and Clinical Criteria need to be completed and faxed as an attachment to process your request. For diagnoses other than PAH, please call the Clinical Support Center at 1-877-309-9493 to request a prior authorization.

LINIOLLE IN ORMATION			
Enrollee's Last Name:	Enrollee's F	irst Name:	
Date of Birth:	Enrollee's N	Nedicaid ID (2 letters, 5 numbers,	, 1 letter):
PRESCRIBER INFORMATION			
Prescriber's Last Name:	Prescriber's	Prescriber's First Name:	
National Provider Identifier (NPI) Number:	Board Certi	Board Certified Specialty:	
Prescriber's Street Address:			
City:	State:	Zip Code	
Prescriber's Phone Number:	Prescriber's	Fax Number:	
REQUESTED PREFERRED DRUG INFORM	ATION		
Drug Name (sildenafil OR tadalafil):			
sildenafil (generic for Revatio®)			
☐ tadalafil (generic for Adcirca®)			
Drug Strength:	Quantity:	Refills:	
Directions:			
New Prescription: Yes No	If <b>NO</b> , date therapy wa	s initiated:	

Enrollee's Last Name:		Enrollee's Fi	Enrollee's First Name:			
RE	REQUESTED NON-PREFERRED DRUG INFORMATION					
Dr	ug Name:					
Drug Strength:		Quantity:	Refills:			
Di	rections:					
Ne	ew Prescription: Yes N	lo If <b>NO</b> , date therapy was	initiated:			
CL	INICAL CRITERIA					
1.	The Food and Drug Administration dose requested is higher, what is	-	s 20 mg TID for Revatio®/sildenafil. If the g the dose?			
2.	What is the diagnosis documented in the patient's chart that requires treatment with a phosphodiesteras type 5 (PDE-5) inhibitor?					
3.	•		disease, or is there documentation in the ertified in pulmonary or cardiovascular			
QI	JESTIONS 4–9 ARE FOR INITIAL	REQUESTS ONLY				
	ease provide all the following valucumentation is required for initia		zation (Questions 4–8). Supporting			
4.	If a right heart catheterization w explains why the patient was una		entation supports the diagnosis and heterization?			
5.	What is the mean pulmonary artery pressure (either at rest or with exercise)? – Supporting documentation required:					
6.	What is the pulmonary artery oc	clusion pressure (wedge pressu	e)? – Supporting documentation required:			
7.	If the wedge pressure is > 15 mm documentation required:	nHg, what is the clinical explanat	tion for high wedge pressure? – Supporting			

Enrollee's Last Name:	Enrollee's First Name:			
CLINICAL CRITERIA (CONTINUED)				
<ul> <li>8. What is the acute pulmonary vasoreactivity (as det documentation required:  <ul> <li>Positive responder</li> <li>Negative responder</li> <li>Not tested – Please provide an explanation for a failed on a calcium channel blocker:</li> </ul> </li> </ul>	ermined during right catheterization)? – Supporting not performing this test and indicate if the patient has			
9. What New York Heart Association/World Health Or patient's current functional status?	ganization (NYHA/WHO) classification describes the			
is available for review upon request of said plan, the	curate and true, and that the supporting documentation NYSDOH or CMS. The submitter understands that any false record to statement that is material to a Medicaid ages under both federal and NYS False Claims Acts.			

For clinical questions or Clinical Drug Review Program questions, please visit <a href="http://newyork.fhsc.com">http://newyork.fhsc.com</a> or call

1-877-309-9493.